RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)
Starting soon · Not applicable
Conditions studied: Chronic Kidney Disease, Type 2 Diabetes
In brief
The goal of this pragmatic randomized clinical trial is to determine whether an Epic-based clinician notification increases initiation of guideline-directed cardio-kidney-metabolic (CKM) therapies in adults with type 2 diabetes and confirmed albuminuria. The main question it aims to answer is: • Does an Epic clinician notification improve initiation of guideline-directed CKM therapies compared with usual care? Researchers will compare an Epic in-basket clinician notification strategy with usual care. In the intervention arm, the treating clinician will receive an Epic notification identifying confirmed albuminuria and potential eligibility for guideline-directed CKM therapies using existing electronic health record (EHR) data. Participants in the usual care arm will receive standard clinical care without notification.
Key facts
- Study ID
- NCT07605390
- Run by
- Baylor Research Institute
- People needed
- 600
- Starts
- 2026-08-01
- Expected to finish
- 2028-01-01
- Last updated by the study team
- 2026-07-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adults aged ≥18 years
- Diagnosis of type 2 diabetes mellitus
- Receiving outpatient care within Baylor Scott \& White Health
- At least 1 outpatient encounter within the preceding 12 months
- Confirmed albuminuria (UACR >30 mg/g)
- Eligible for one or more guideline-directed CKM therapies based on - prespecified clinical criteria and EHR review
You may not qualify if…
- Type 1 diabetes mellitus
- Contraindication or documented intolerance to all eligible guideline-directed CKM therapies
- Advanced kidney dysfunction below recommended initiation thresholds for SGLT2i or finerenone
- Hyperkalemia or elevated baseline serum potassium precluding safe therapy initiation
- Contraindicated drug interactions (e.g., strong CYP3A inhibitors with finerenone)
- Other guideline- or labeling-based contraindications to therapy initiation
Where it is running
- Baylor Scott and White Health — Dallas, Texas, United States
- Baylor Scott and White, Advanced Heart Care — Plano, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.